1stOncology™: Cancer Intelligence Service – Page 8572 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Philogen S.p.A. announces its Half Year 2021 Results on Tuesday 28th September 2021

On September 6, 2021 Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-and small molecule-based targeted therapeutics, reported that it will announce its Interim Results for the six month ended 30th June 2021 following a Board of Director’s meeting to be held on Tuesday 28th September 2021 (Press release, Philogen, SEP 6, 2021, View Source [SID1234587271]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief Financial Officer, Dr. Christian Lizak, and Dr. Emanuele Puca will host a virtual briefing for sell-side analysts at 12:00 ET / 17:00 BST / 18:00 CEST on September 29, 2021.

For more details or to attend the virtual briefing, please contact [email protected].

ERYTECH to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

On September 6, 2021 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, reported that its CEO, Gil Beyen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference (Press release, ERYtech Pharma, SEP 6, 2021, https://erytech.com/erytech-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference/ [SID1234587270]). The Conference will be held virtually with all participants joining remotely from September 13th – 15th, 2021.

TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB

On September 6, 2021 TB Alliance reported that it has granted global pharma major Lupin Limited (Lupin), a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug "BPaL" regimen (Press release, Lupin, SEP 6, 2021, View Source [SID1234587269]). Lupin intends to commercialize the anti-tuberculosis (TB) medicine in approximately 140 countries and territories, including many of the highest TB burden countries around the world.

"TB Alliance is committed to ensure its products are widely available and affordable to those who need them," said Mel Spigelman, President and CEO, TB Alliance. "Partnering with Lupin, a well-established manufacturer with experience delivering high quality TB therapies, will help further enable widespread access to our novel regimen while promoting a competitive market to drive affordability."

Nilesh Gupta, Managing Director, Lupin added, "As a global leader in anti-TB medicines, Lupin is committed to enhancing access to bridge unmet needs in countries where it is needed the most. This collaboration with TB Alliance leverages our strength and expertise to contribute to better global health."
"Tuberculosis is one of humanity’s oldest, deadliest, and most persistent diseases. Lupin is the largest supplier of first-line anti-TB drugs in the world, and we are excited to partner with TB Alliance to help bring new therapies for highly drug-resistant TB to reach individuals and countries where access to these medicines is so urgently needed," said Naresh Gupta, President API Plus, Lupin.

About Tuberculosis
TB, in all forms, must be treated with a combination of drugs; the most drug-sensitive forms of TB are typically treated for six months using four anti-TB drugs. An estimated 1.5 million people died of TB in 2020, according to the World Health Organization (WHO), although the precise numbers are not known and recent research suggests that TB could have killed as much as half a million more people in that same year.

Drug-resistant TB develops when the long, complex, decades-old TB drug regimen is improperly administered, or when people with TB stop taking their medicines before the disease has been fully eradicated from their body—highlighting the urgent need to develop better and shorter treatment regimens. Once a drug-resistant strain has developed, it can be transmitted directly to others through the air, just like drug-sensitive TB. There are over half a million cases of drug-resistant TB each year and its spread undermines efforts to control the TB pandemic.

Selvita will develop a platform to produce focused libraries of bioactive compounds with the use of machine learning and AI methods

On September 6, 2021 Selvita, one of the largest preclinical contract research organizations in Europe, reported that it had received a grant funding of 1 M EUR to create a novel technological platform which will accelerate the drug discovery process (Press release, Selvita, SEP 6, 2021, View Source;utm_medium=rss&utm_campaign=selvita-will-develop-a-platform-to-produce-focused-libraries-of-bioactive-compounds-with-the-use-of-machine-learning-and-ai-methods [SID1234587267]). The grant came from the National Centre of Research and Development with a total of 1.7 M EUR dedicated to the project. The project will enable Company to implement new services for biotech and pharma clients.

The aim of the project is to significantly improve the early stages of the drug discovery process, leading to the identification of the first active substance which will undergo further development. Usually, this is done by searching large libraries of randomly selected chemicals, which are mostly inactive and not novel. This, however, results in a low probability of finding a compound with the desired biological profile worth pursuing further. It is also a very time-consuming and expensive process. In order to mitigate these problems, Selvita will create a service platform, called ProBiAI, that will use much smaller libraries of compounds with targeted biological properties using novel structures. This platform will integrate structure design, parallel synthesis and automatic compound purification, all of which will be optimized using artificial intelligence methods. What distinguishes this type of libraries is a much greater probability of identifying biologically active substances with better patentability, faster and cheaper.

Development of innovative compounds with therapeutic potential and a good IP position, which can be executed within an optimal time and budget, is one of the greatest challenges that biotechnology and pharmaceutical companies are currently facing. The aim of our project is to optimize the initial stages of the drug discovery process, including the design of compound structures with therapeutic potential, as well as the effective synthesis and purification of the designed target compound libraries.

To achieve our goal, we intend to create a platform that integrates the design of structures and the planning of parallel synthesis and automatic purification, based on the available scientific data, using artificial intelligence methods. Our platform will not only help to accelerate the process of discovering new drugs but will also increase the likelihood of discovering effective therapies, which may be of particular interest to our clients – comments Mirosława Zydroń, PhD Eng, Member of the Management Board and Director of the Chemistry Department at Selvita S.A.

Scandion Oncology receives approval for initiating the CORIST part 2 trial

On September 6, 2021 Scandion Oncology A/S, the Cancer Drug Resistance Company, reported that the company has obtained approval from the Danish Medicines Agency and the Ethics Com-mittee in Denmark of the amendment of part 2 of the CORIST Phase II study (Press release, Scandion Oncology, SEP 6, 2021, View Source,c3410221 [SID1234587265]). This means that the company can commence the inclusion of patients. To increase the recruitment rate, Scandion Oncology is expanding the number of sites in Denmark from 2 to 5 and will further add additional sites in the EU.

"With this approval, we can now commence part 2 of this seminal study. This next step in our journey will target a clear proof-of-concept to create clarity in order to make a difference for patients and create value for our shareholders. To accelerate the recruitment rate, we are opening additional sites and expect a read-out in Q2-Q3, 2022. We will communicate more about our plans and strategy at our upcoming Capital Markets Day on September 8," said Bo Rode Hansen, President and CEO of Scandion Oncology.

On June 24, Scandion Oncology reported positive results from the dose-finding part 1 of the CORIST Phase II study. A well tolerated dose of SCO-101 in combination with the chemotherapy regimen FOLFIRI was determined and the treatment resulted in notable potentiation of FOLFIRI. Scandion Oncology also identified the oncogene RAS as a predictive biomarker, which led the company to making an amendment to the clinical protocol, optimizing the inclusion of patients and de-risking the study.

The design for part 2 of the study (the proof-of-concept arm) is a standard single arm Phase II study with the aim of assessing preliminary effect and further evaluating safety and tolerability of SCO-101 in combination with FOLFIRI. The primary efficacy objective is assessment of response (tumor reduction) and secondary objectives include assessment of Clinical benefit (The duration of Stable Disease, Progression Free Survival (PFS), Overall Survival (OS)) as well as biomarker assessment and correlation to treatment tolerability and outcome. Part 2 of the CORIST Phase II study will include up to 25 patients.

This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on September 6, 2021, at 8:30 CET